Sansure Biotech Full Year 2024 Earnings: EPS: CN¥0.44 (vs CN¥0.62 in FY 2023)

Simply Wall St

March 04, 2025

Sansure Biotech (SHSE:688289) Full Year 2024 Results

Key Financial Results

Revenue: CN¥1.50b (up 49% from FY 2023).
Net income: CN¥259.0m (down 29% from FY 2023).
Profit margin: 17% (down from 36% in FY 2023). The decrease in margin was driven by higher expenses.
EPS: CN¥0.44 (down from CN¥0.62 in FY 2023).

earnings-and-revenue-growth — SHSE:688289 Earnings and Revenue Growth March 4th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sansure Biotech Earnings Insights

Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in China.

Performance of the Chinese Medical Equipment industry.

The company's shares are down 4.9% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Sansure Biotech has 2 warning signs (and 1 which shouldn't be ignored) we think you should know about.

If you're looking to trade Sansure Biotech, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.